BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1010 related articles for article (PubMed ID: 33117354)

  • 1. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
    Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
    Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
    Lee BM; Seong J
    World J Gastroenterol; 2021 Mar; 27(10):919-927. PubMed ID: 33776363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
    Hou J; Zhang H; Sun B; Karin M
    J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
    Chami P; Diab Y; Khalil DN; Azhari H; Jarnagin WR; Abou-Alfa GK; Harding JJ; Hajj J; Ma J; El Homsi M; Reyngold M; Crane C; Hajj C
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
    Guardascione M; Toffoli G
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
    Armstrong SA; He AR
    Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Pinter M; Scheiner B; Peck-Radosavljevic M
    Gut; 2021 Jan; 70(1):204-214. PubMed ID: 32747413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
    Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
    Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.
    Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T
    PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.